Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck puts money on Arcoxia

Executive Summary

Merck raises 2007 earnings guidance on the assumption that Arcoxia (etoricoxib), its follow-on product to the withdrawn arthritis medication Vioxx, will be approved by FDA, the company announces Dec. 6. The Arcoxia NDA has a user fee action date in April 2007 following Merck's submission of a response to FDA's November 2004 "approvable" letter (1"The Pink Sheet" Nov. 13, 2006, In Brief). The submission limits the proposed indication for the COX-2 inhibitor, which has been approvable since October 2004, to osteoarthritis. Merck anticipates that 2007 earnings per share will be in the range of $2.36 to $2.49. "Other sales," which includes products Arcoxia, Januvia and Proscar among many others, is expected to be between $5.2 billion and $5.6 bil...

You may also be interested in...

EU Notified Body Association Takes Steps To Allay EC’s Virtual Audit Fears

The European Commission has reluctantly allowed virtual audits in the context of new MDR and IVDR. The EU notified body association is helping the collective effort to meet its strict requirements.

New UK Biosimilars Pathway Suffers Setback

The UK’s implementation of a new national licensing framework for biosimilars has been pushed back from the start of 2021, with the MHRA citing “intense COVID-19 activities” as the cause of an indefinite delay in the consultation process.

Hikma Suspends Roll-Out Of Advair Rival

Hikma has temporarily stopped the roll-out of its rival to Advair Diskus in the US after it filed an amendment to its ANDA over packaging controls.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts